Literature DB >> 16918328

Tachykinins in the respiratory tract.

David A Groneberg1, Selena Harrison, Q Thai Dinh, Pierangelo Geppetti, Axel Fischer.   

Abstract

Tachykinins as substance P and neurokinin A belong to a family of peptides, which are released from airway nerves after noxious stimulation. They influence numerous respiratory functions under both normal and pathological conditions including the regulation of airway smooth muscle tone, vascular tone, mucus secretion and immune functions. For the most part the synthesis/release of tachykinins is associated with neuronal cells; nevertheless, inflammatory and immune cells can synthesize and release tachykinins under certain physiological conditions. Moreover, this second cellular source of tachykinins may play an important role in inflammatory airway diseases such as bronchial asthma or chronic obstructive pulmonary disease (COPD). Dual tachykinin (NK1 and NK2) receptor antagonists demonstrate a significant bronchoprotection and a possible future role in the development of novel therapeutic approaches. In addition, NK3 receptors could also possess a bronchoprotective action, however, their presence in the human respiratory tract still needs to be confirmed. The family of tachykinins has recently been extended by the discovery of a third tachykinin gene that encodes the previously unknown NK1 receptor selective tachykinins hemokinin 1, endokinin A and B. Together with other novel tachykinin peptides such as C14TKL-1 and virokinin further research is required to define their respiratory biological role in health and disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16918328     DOI: 10.2174/138945006778019318

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  13 in total

1.  Neurokinin-neurotrophin interactions in airway smooth muscle.

Authors:  Lucas W Meuchel; Alecia Stewart; Dan F Smelter; Amard J Abcejo; Michael A Thompson; Syed I A Zaidi; Richard J Martin; Y S Prakash
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-04-22       Impact factor: 5.464

Review 2.  Neurotrophins in lung health and disease.

Authors:  Ys Prakash; Michael A Thompson; Lucas Meuchel; Christina M Pabelick; Carlos B Mantilla; Syed Zaidi; Richard J Martin
Journal:  Expert Rev Respir Med       Date:  2010-06       Impact factor: 3.772

Review 3.  Brain-derived neurotrophic factor in the airways.

Authors:  Y S Prakash; Richard J Martin
Journal:  Pharmacol Ther       Date:  2014-02-19       Impact factor: 12.310

4.  Reproductive, Physiological, and Molecular Outcomes in Female Mice Deficient in Dhh and Ihh.

Authors:  Chang Liu; Karina F Rodriguez; Paula R Brown; Humphrey H-C Yao
Journal:  Endocrinology       Date:  2018-07-01       Impact factor: 4.736

Review 5.  Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance.

Authors:  Marilina García-Aranda; Teresa Téllez; Lauraine McKenna; Maximino Redondo
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

6.  The effect of substance P on asthmatic rat airway smooth muscle cell proliferation, migration, and cytoplasmic calcium concentration in vitro.

Authors:  Miao Li; Yun-Xiao Shang; Bing Wei; Yun-Gang Yang
Journal:  J Inflamm (Lond)       Date:  2011-07-21       Impact factor: 4.981

Review 7.  Tachykinin receptors antagonism for asthma: a systematic review.

Authors:  Renata Ramalho; Raquel Soares; Nuno Couto; André Moreira
Journal:  BMC Pulm Med       Date:  2011-08-02       Impact factor: 3.317

Review 8.  Beta-Adrenergic Agonists.

Authors:  Giovanni Barisione; Michele Baroffio; Emanuele Crimi; Vito Brusasco
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-30

9.  Effect of montelukast on platelet activating factor- and tachykinin induced mucus secretion in the rat.

Authors:  Rene Schmidt; Petra Staats; David A Groneberg; Ulrich Wagner
Journal:  J Occup Med Toxicol       Date:  2008-02-20       Impact factor: 2.646

10.  Investigation of Neurokinin-1 Receptor Antagonism as a Novel Treatment for Chronic Bronchitis in Dogs.

Authors:  M Grobman; C Reinero
Journal:  J Vet Intern Med       Date:  2016-03-20       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.